Optical Coherence Tomographic Patterns of Diabetic Macular Edema

Kim, Brian Y.; Smith, Scott D.

doi:10.1016/j.ajo.2006.04.023

Cited by 244 publications

(183 citation statements)

References 38 publications

Supporting

Mentioning

164

Contrasting

Unclassified

Order By: Relevance

“…SRD is defined as subfoveal accumulation of fluid within a well defined area of retinal detachment. [7][8][9][10][11] Bevacizumab is a complete full-length humanized antibody that binds to all subtypes of vascular endothelial growth factor and its intravitreal administration has been proved in several studies to be effective in the treatment of diabetic macular oedema (DMO). However, only a few publications addressed the issue of why some eyes respond to this treatment better than others.…”

Section: Introductionmentioning

confidence: 99%

“…[1][2][3][4] Besides making the objective diagnosis and quantitative evaluation of macular oedema possible, optical coherence tomography (OCT) offers the opportunity to assess in vivo histologic cross-sections of the healthy and diseased retina, leading to a better understanding of pathologic processes. 5,6 Three different morphologic subtypes of macular oedema were defined according to OCT: 7,8 Sponge-like diffuse retinal thickening (DRT), cystoid macular oedema (CMO) and serous retinal detachment (SRD). DRT, which is reflected as diffuse thickening of retina with reduced intraretinal reflectivity on OCT, is assumed to be caused by intracytoplasmic swelling of Mü ller cells in the outer plexiform layer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of a single intravitreal bevacizumab injection on different optical coherence tomographic patterns of diabetic macular oedema

Koytak

Altınışık

Sarı

et al. 2013

Eye

View full text Add to dashboard Cite

Purpose The aim of this study is to compare the therapeutic effect of a single intravitreal bevacizumab (IVB) injection in eyes with diabetic macular oedema (DMO) of different patterns determined by optical coherence tomography (OCT). Methods Medical records of patients who had a single IVB injection for DMO were analysed retrospectively. Eyes with a clinically significant DMO and a central foveal thickness (CFT) of 250 lm or more determined by OCT were included in the analysis. Best-corrected visual acuity (BCVA), CFT and total macular volume values before and after the injection were recorded. Eyes were divided into sponge-like diffuse retinal thickening (DRT), cystoid macular oedema (CMO) and serous retinal detachment (SRD) groups according to the morphology on OCT. Results A total of 92 eyes (42 with DRT, 31 with CMO and 19 with SRD) were included in the study. There was no statistically significant variation between three groups regarding the change in BCVA (P ¼ 0.695). CMO and SRD groups had greater reductions in their mean CFT, and the amount of reduction showed statistically significant variation between three groups (P ¼ 0.048). However, no statistically significant difference was found between groups in terms of percentage of change in CFT (P ¼ 0.278). Conclusion CMO and SRD subtypes are associated with a greater reduction in the CFT than the DRT subtype. Although the change in BCVA was not significantly different between groups, the DRT group showed markedly better visual improvement in proportion to the decrease in CFT.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Effect of a single intravitreal bevacizumab injection on different optical coherence tomographic patterns of diabetic macular oedema

Koytak

Altınışık

Sarı

et al. 2013

Eye

View full text Add to dashboard Cite

show abstract

“…In addition, OCT produces cross-sectional images of the retina that have been found to correlate well with retinal histology as demonstrated by light microscopy (12) .…”

Section: Discussionmentioning

confidence: 99%

“…Diabetic macular edema is a well-documented, sight threatening complication of DM, Previously described methods of assessing DME include contact and noncontact slit-lamp bio microscopy, indirect fundosocopy, fluorescein angiography, and fundus stereo-photograph (12) .…”

Section: Discussionmentioning

confidence: 99%

“…Stereoscopic examination of the fundus at the slit-lamp or on stereoscopic color fundus photographs is the standard method, as defined by the Early Treatment Diabetic Retinopathy Study (ETDRS), for evaluating macular thickening and for starting treatment when the clinical significant macular edema level has been reached (12) .…”

Section: Proliferative Diabetic Retinopathy (Pdr)mentioning

confidence: 99%

See 1 more Smart Citation

The Effect of Aflibercept and Ranibizumab in Patients with Diabetic Macular Edema: A comparative Study

Eid

Hamed²,

Hudieb³

2018

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Diabetic macular edema is one of the most significant causes of blindness and severe visual impairment in patients with diabetes, which can result in reduced quality of life. Three commonly used intravitreous VEGF inhibitors aflibercept, bevacizumab and ranibizumab have been shown to be beneficial and relatively safe for the treatment of diabetic macular edema, but only aflibercept and ranibizumab are approved by the Food and Drug Administration (FDA) for this indication. Aim of the Work: To compare between the effect of ranibizumab and aflibercept in patients with diabetic macular edema as a diabetic retinopathy complication that leads to visual impairment. Patients and Methods: A prospective study of 20 patients (20 eyes) was conducted in Al-Mouneer diabetic eye center with three times injection one month apart. The patients were divided into two groups, Group A was consisted of 10 patients who received ranibizumab as 0.5 mg (0.05ml of 10mg/ml solution) an intra vitreal injection. Group B was consisted of 10 patients who received aflibercept 2 mg (0.05mL of 40mg/ml solution) as an intra vitreal injection with follow up for three months. Results: A statistically significant difference over the time through BCVA and central macular thickness with ranibizumab. There was also a statistically significant difference over the time through BCVA, central macular thickness and IOP with aflibercept. Conclusion: There was more improvement in BCVA which was significant and more reduction in central macular thickness with ranibizumab than with aflibercept. Recommendations: Larger group studies to confirm our results; longer term study for the effect of ranibizumab and aflibercept injection on the central macular thickness and IOP and comparing the effect of single injection versus multiple injections. Searching for the causes of resistance or delayed response to the intravitreal injections in some patients.

show abstract

Vitrectomy as an Adjunct to Treat-and-Extend Anti-VEGF Injections for Diabetic Macular Edema

Maguire,

Laidlaw,

Hammond

et al. 2024

JAMA Ophthalmol

View full text Add to dashboard Cite

ImportanceThere are reported benefits from vitrectomy for diabetic macular edema (DME); however, data precede anti–vascular endothelial growth therapy (VEGF) therapy, supporting a need to assess the current role of vitrectomy.ObjectiveTo determine rates of recruitment and efficacy outcomes of vitrectomy plus internal limiting membrane (ILM) peeling adjunctive to treat-and-extend (T&amp;E) anti-VEGF injections for diabetic macular edema (DME).Design, Setting, and ParticipantsThis was a single-masked, multicenter randomized clinical trial at 21 sites in the United Kingdom from June 2018 to January 2021, evaluating single eyes of treatment-naive patients with symptomatic vision loss from DME for less than 1 year. Inclusion criteria were best-corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study letter score greater than 35 (approximate Snellen equivalent, 20/200 or better) and central subfield thickness (CST) greater than 350 μm after 3 monthly intravitreal injections of ranibizumab or aflibercept. Data analysis was performed in July 2023.InterventionsPatients were randomized 1:1 into vitrectomy plus standard care or standard care alone and further stratified into groups with vs without vitreomacular interface abnormality. Both groups received a T&amp;E anti-VEGF injection regimen with aflibercept, 2 mg, or ranibizumab, 0.5 mg. The vitrectomy group additionally underwent pars plana vitrectomy with epiretinal membrane or ILM peel within 1 month of randomization.Main Outcomes and MeasuresRate of recruitment and distance BCVA. Secondary outcome measures were CST, change in BCVA and CST, number of injections, rate of completed follow-up, and withdrawal rate.ResultsOver 32 months, 47 of a planned 100 patients were enrolled; 42 (89%; mean [SD] age, 63 [11] years; 26 [62%] male) completed 12-month follow-up visits. Baseline characteristics appeared comparable between the control (n = 23; mean [SD] age, 66 [10] years) and vitrectomy (n = 24; mean [SD] age, 62 [12] years) groups. No difference in 12-month BCVA was noted between groups, with a 12-month median (IQR) BCVA letter score of 73 (65-77) letters (Snellen equivalent, 20/40) in the control group vs 77 (67-81) letters (Snellen equivalent, 20/32) in the vitrectomy group (difference, 4 letters; 95% CI, −8 to 2; P = .24). There was no difference in BCVA change from baseline (median [IQR], −1 [−3 to 2] letters for the control group vs −2 [−8 to 2] letters for the vitrectomy group; difference, 1 letter; 95% CI, −5 to 7; P = .85). No difference was found in CST changes (median [IQR], −94 [−122 to 9] μm for the control group vs −32 [−48 to 25] μm for the vitrectomy group; difference, 62 μm; 95% CI, −110 to 11; P = .11).Conclusions and RelevanceEnrollment goals could not be attained. However, with 47 participants, evidence did not support a clinical benefit of vitrectomy plus ILM peeling as an adjunct to a T&amp;E regimen of anti-VEGF therapy for DME.Trial Registrationisrctn.org Identifier: ISRCTN59902040

show abstract

Optical Coherence Tomographic Patterns of Diabetic Macular Edema

Cited by 244 publications

References 38 publications

Effect of a single intravitreal bevacizumab injection on different optical coherence tomographic patterns of diabetic macular oedema

Effect of a single intravitreal bevacizumab injection on different optical coherence tomographic patterns of diabetic macular oedema

The Effect of Aflibercept and Ranibizumab in Patients with Diabetic Macular Edema: A comparative Study

Vitrectomy as an Adjunct to Treat-and-Extend Anti-VEGF Injections for Diabetic Macular Edema

Contact Info

Product

Resources

About